PLoS ONE (Jan 2013)

RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.

  • Sakiko Sanada,
  • Kazunobu Futami,
  • Atsumu Terada,
  • Koji Yonemoto,
  • Sachiko Ogasawara,
  • Jun Akiba,
  • Makiko Yasumoto,
  • Akiko Sumi,
  • Kimio Ushijima,
  • Toshiharu Kamura,
  • Yasuhiro Furuichi,
  • Hirohisa Yano

DOI
https://doi.org/10.1371/journal.pone.0072820
Journal volume & issue
Vol. 8, no. 8
p. e72820

Abstract

Read online

OBJECTIVE: This study analyzed the clinicopathological correlation between ovarian cancer (OC) and RECQL1 DNA helicase to assess its therapeutic potential. METHODS: Surgically resected OC from 118 retrospective cases, for which paraffin blocks and all clinical data were complete, were used in this study. RECQL1 and Ki-67 immunostaining were performed on sections to correlate RECQL1 staining with subtype and patient survival. Ten OC and two normal cell lines were then examined for RECQL1 expression and were treated with siRNA against RECQL1 to assess its effect on cell proliferation. RESULTS: Of the 118 cases of adenocarcinoma (50, serous; 26, endometrioid; 21, clear cell; 15, mucinous; 6, other histology), 104 (90%) showed varying levels of RECQL1 expression in the nuclei of OC cells. The Cox hazards model confirmed that diffuse and strong staining of RECQL1 was correlated with histological type. However, RECQL1 expression did not correlate with overall patient survival or FIGO stage. In vitro, RECQL1 expression was exceptionally high in rapidly growing OC cell lines, as compared with normal cells. Using a time-course analysis of RECQL1-siRNA transfection, we observed a significant inhibition in cell proliferation. CONCLUSIONS: RECQL1 DNA helicase is a marker of highly proliferative cells. RECQL1-siRNA may offer a new therapeutic strategy against various subtypes of OC, including platinum-resistant cancers, or in recurrent cancers that gain platinum resistance.